Aydin Turkmen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aydin Turkmen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Erol Demir
Transplant Immunology Research Center of Excellence (TIREX), Koç University School of Medicine, Istanbul, Turkey
5 shared publications - Ahmet Burak Dirim
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3 shared publications - Halil Yazici
Division of Nephrology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye
3 shared publications - Hayriye Senturk Ciftci
Department of Medical Biology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
3 shared publications - Seda Safak
Department of Nephrology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Türkiye
3 shared publications - Ayse Serra Artan
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Cambridge University Press (CUP) in The Aeronautical Journal
- Vol. 130 (1351) , 1-18
Aircraft takeoff speed prediction with deep learning: a comparative study of MLP, 1D-CNN, LSTM and attention-based architectures on Boeing 737-300 data
Modern aviation supports an ever-broader range of civil and military missions, and the airframes designed for these missions must satisfy stringent safety and performance requirements. The takeoff and landing phases are the most accident-prone portions of a flight despite representing only a short interval of the total block time, which makes the accurate prediction of takeoff speed a safety-relevant problem. A previous machine learning study addressed the takeoff-speed prediction problem of the Boeing 737-300 with classical regressors using pressure altitude, outside air temperature, gross weight and flap angle as the predictors. In the present work, the same regression problem is revisited under the deep learning paradigm. Four neural architectures are trained on an identical pre-processing pipeline and train-validation partition, namely a multilayer perceptron, a one-dimensional convolutional network, a long short-term memory network and a wide-and-deep architecture incorporating multi-head self-attention. Among the four candidates, the long short-term memory network attains the lowest root mean square error and mean square error on the unseen test file and is subsequently subjected to Bayesian hyperparameter optimisation through the Keras Tuner library. The predicted and the measured takeoff speeds are reported side by side for the first time in the deep learning literature for this airframe, and the simulation results indicate that the developed networks constitute an effective alternative tool for takeoff-speed prediction.
- 23 June 2026
- Published by Cambridge University Press (CUP) in The Aeronautical Journal
- Vol. 130 (1351) , 1-18
Open AccessAircraft takeoff speed prediction with deep learning: a comparative study of MLP, 1D-CNN, LSTM and attention-based architectures on Boeing 737-300 data
Modern aviation supports an ever-broader range of civil and military missions, and the airframes designed for these missions must satisfy stringent safety and performance requirements. The takeoff and landing phases are the most accident-prone portions of a flight despite representing only a short interval of the total block time, which makes the accurate prediction of takeoff speed a safety-relevant problem. A previous machine learning study addressed the takeoff-speed prediction problem of the Boeing 737-300 with classical regressors using pressure altitude, outside air temperature, gross weight and flap angle as the predictors. In the present work, the same regression problem is revisited under the deep learning paradigm. Four neural architectures are trained on an identical pre-processing pipeline and train-validation partition, namely a multilayer perceptron, a one-dimensional convolutional network, a long short-term memory network and a wide-and-deep architecture incorporating multi-head self-attention. Among the four candidates, the long short-term memory network attains the lowest root mean square error and mean square error on the unseen test file and is subsequently subjected to Bayesian hyperparameter optimisation through the Keras Tuner library. The predicted and the measured takeoff speeds are reported side by side for the first time in the deep learning literature for this airframe, and the simulation results indicate that the developed networks constitute an effective alternative tool for takeoff-speed prediction.
- Open Access
- 19 October 2025
- Published by Journal of Aviation in Journal of Aviation
- Vol. 9 (3) , 497-502
Design and Implementation of a UAV Control System Using the Airbus A320 Side-Stick Controller
Air transportation has become a rapidly expanding and widely preferred mode of international and intercontinental travel. In line with this growth, aircraft manufacturers continuously strive to enhance both flight safety and comfort for passengers as well as flight crews. One of the most significant examples of these efforts is the side-stick controller employed in Airbus aircraft, which plays a vital role in improving flight safety and operational efficiency. The side-stick is a fundamental control device that facilitates the pilot’s handling of the aircraft. Pilot inputs made in the cockpit are transmitted via the side-stick and used as reference signals for the actuation of the flight control surfaces. These signals are then processed by the flight control computers, which determine the corresponding movements of the control surfaces. In this way, cockpit commands are converted into electrical signals, enabling precise aircraft control through the flight control system.
- 19 October 2025
- Published by Journal of Aviation in Journal of Aviation
- Vol. 9 (3) , 497-502
Open AccessDesign and Implementation of a UAV Control System Using the Airbus A320 Side-Stick Controller
Air transportation has become a rapidly expanding and widely preferred mode of international and intercontinental travel. In line with this growth, aircraft manufacturers continuously strive to enhance both flight safety and comfort for passengers as well as flight crews. One of the most significant examples of these efforts is the side-stick controller employed in Airbus aircraft, which plays a vital role in improving flight safety and operational efficiency. The side-stick is a fundamental control device that facilitates the pilot’s handling of the aircraft. Pilot inputs made in the cockpit are transmitted via the side-stick and used as reference signals for the actuation of the flight control surfaces. These signals are then processed by the flight control computers, which determine the corresponding movements of the control surfaces. In this way, cockpit commands are converted into electrical signals, enabling precise aircraft control through the flight control system.
- Open Access
- 19 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5858
Malignancies After Renal Transplantation: Frequency, Etiology, and Prognosis—A Single Center Experience
Introduction and Aim: Renal transplant recipients face significant long-term graft and patient loss due to post-transplant malignancies. This study aimed to characterize post-transplant malignancies, determine mortality risk factors, and evaluate patient outcomes. Materials and Methods: This retrospective study included 2052 kidney transplant recipients who underwent transplantation between 1976 and 2019 at our institution, other national centers, or international facilities, and who had at least six months of follow-up. Regardless of the transplant center, all patients were followed exclusively at our nephrology department for post-transplant care. A comprehensive review of patient files was conducted, encompassing demographic data, malignancy type and treatment, mortality rates, tissue compatibility assessments, viral serology results, immunosuppression protocols, acute rejection history, and pre-transplant malignancies. The relationships between these variables and mortality were examined. Results: A total of 167 malignant events were observed in 163 patients out of 2052 renal transplant patients (7.9%). The female patients comprised 34.4% (n = 56) of the participants. Ages at transplantation and malignancy diagnosis had medians of 40.0 (13–72) and 50.0 (23–78) years, respectively. The leading malignancy was skin cancer at 30.0%, with Kaposi sarcoma at 11.3% and post-transplant lymphoproliferative disease at 10.6% following. Of the patients followed up, 58.9% (93 patients) had mortality. In univariate analysis, older age at transplant, older age at malignancy diagnosis, and male sex were associated with mortality; however, no independent predictors were identified in the multivariate model (all p > 0.05), likely due to sample size limitations and inter-variable collinearity. Mortality showed statistically significant associations (p < 0.05) with increased age at transplantation, increased age at malignancy diagnosis, and male gender. Conclusions: Post-transplant malignancies significantly compromise both graft longevity and patient survival. Particularly aggressive skin cancers demand heightened clinical vigilance. Early detection through regular dermatological screening, patient education, and timely biopsies must become integral to long-term transplant care protocols.
- 19 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5858
Open AccessMalignancies After Renal Transplantation: Frequency, Etiology, and Prognosis—A Single Center Experience
Introduction and Aim: Renal transplant recipients face significant long-term graft and patient loss due to post-transplant malignancies. This study aimed to characterize post-transplant malignancies, determine mortality risk factors, and evaluate patient outcomes. Materials and Methods: This retrospective study included 2052 kidney transplant recipients who underwent transplantation between 1976 and 2019 at our institution, other national centers, or international facilities, and who had at least six months of follow-up. Regardless of the transplant center, all patients were followed exclusively at our nephrology department for post-transplant care. A comprehensive review of patient files was conducted, encompassing demographic data, malignancy type and treatment, mortality rates, tissue compatibility assessments, viral serology results, immunosuppression protocols, acute rejection history, and pre-transplant malignancies. The relationships between these variables and mortality were examined. Results: A total of 167 malignant events were observed in 163 patients out of 2052 renal transplant patients (7.9%). The female patients comprised 34.4% (n = 56) of the participants. Ages at transplantation and malignancy diagnosis had medians of 40.0 (13–72) and 50.0 (23–78) years, respectively. The leading malignancy was skin cancer at 30.0%, with Kaposi sarcoma at 11.3% and post-transplant lymphoproliferative disease at 10.6% following. Of the patients followed up, 58.9% (93 patients) had mortality. In univariate analysis, older age at transplant, older age at malignancy diagnosis, and male sex were associated with mortality; however, no independent predictors were identified in the multivariate model (all p > 0.05), likely due to sample size limitations and inter-variable collinearity. Mortality showed statistically significant associations (p < 0.05) with increased age at transplantation, increased age at malignancy diagnosis, and male gender. Conclusions: Post-transplant malignancies significantly compromise both graft longevity and patient survival. Particularly aggressive skin cancers demand heightened clinical vigilance. Early detection through regular dermatological screening, patient education, and timely biopsies must become integral to long-term transplant care protocols.
- Open Access
- 10 February 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (3) , 364-369
The evaluation of the relationship between anti angiotensin type I antibodies in hypertensive patients undergoing kidney transplantation
Objectives: We aimed to compare the anti-angiotensin II type I receptor (AT1R) antibody levels considering the development of anti-HLA antibodies after transplantation, pathologically confirmed humoral or vascular rejection reactions and late complications. Methods: Forty-nine hypertensive patients who had presented to the Division of Nephrology, Transplantation Outpatient Clinic of Memorial Health Group Hospitals Transplant Units and Istanbul Medical Faculty for live kidney transplantation and underwent transplantation between 2015 and 2019, were included in our study. Among our patients (29 males/20 females), 76 % had primary hypertension, and 24 % had secondary hypertension. In this study, serum AT1R antibody levels before and after transplantation were measured using the Enzyme-Linked ImmunoSorbent Assay (ELISA) method. The anti-HLA antibody was detected with the Luminex method using the single antigen bead (SAB) assay. Results: The AT1R antibody was found positive in 7 (18.9 %) of 37 patients who had primary hypertension and in 4 (33.3 %) of 12 patients who had secondary hypertension (p=0.426). The examination of the frequencies of development of post-transplant anti-HLA antibodies showed that the frequency of AT1R antibody positivity was found higher in the group with positive anti-HLA antibodies compared to the levels in the group with negative anti-HLA antibodies (p=0.002). The comparison of the pre-transplant and post-transplant values showed that the AT1R antibody level was statistically significantly decreased after transplantation [7.3/6.6 (3.2–21.1) vs. 6.2/4.7 (1.5–24.5), p=0.001]. Conclusions: The findings of our study suggest that the evaluation of the AT1R antibody levels among non-HLA antibodies may be important for predicting the immunological risk before transplantation.
- 10 February 2025
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 50 (3) , 364-369
Open AccessThe evaluation of the relationship between anti angiotensin type I antibodies in hypertensive patients undergoing kidney transplantation
Objectives: We aimed to compare the anti-angiotensin II type I receptor (AT1R) antibody levels considering the development of anti-HLA antibodies after transplantation, pathologically confirmed humoral or vascular rejection reactions and late complications. Methods: Forty-nine hypertensive patients who had presented to the Division of Nephrology, Transplantation Outpatient Clinic of Memorial Health Group Hospitals Transplant Units and Istanbul Medical Faculty for live kidney transplantation and underwent transplantation between 2015 and 2019, were included in our study. Among our patients (29 males/20 females), 76 % had primary hypertension, and 24 % had secondary hypertension. In this study, serum AT1R antibody levels before and after transplantation were measured using the Enzyme-Linked ImmunoSorbent Assay (ELISA) method. The anti-HLA antibody was detected with the Luminex method using the single antigen bead (SAB) assay. Results: The AT1R antibody was found positive in 7 (18.9 %) of 37 patients who had primary hypertension and in 4 (33.3 %) of 12 patients who had secondary hypertension (p=0.426). The examination of the frequencies of development of post-transplant anti-HLA antibodies showed that the frequency of AT1R antibody positivity was found higher in the group with positive anti-HLA antibodies compared to the levels in the group with negative anti-HLA antibodies (p=0.002). The comparison of the pre-transplant and post-transplant values showed that the AT1R antibody level was statistically significantly decreased after transplantation [7.3/6.6 (3.2–21.1) vs. 6.2/4.7 (1.5–24.5), p=0.001]. Conclusions: The findings of our study suggest that the evaluation of the AT1R antibody levels among non-HLA antibodies may be important for predicting the immunological risk before transplantation.
- Open Access
- 12 May 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-13
COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic
Background: Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods: Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results: Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47–66]), first- (56 mL/min [IQR, 51–68]), third- (51 mL/min [IQR,48–67]) and sixth-months (52 mL/min [IQR, 48–81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions: Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode.
- 12 May 2022
- Published by Springer Nature in BMC Nephrology
- Vol. 23 (1) , 1-13
Open AccessCOVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic
Background: Kidney transplant recipients have an increased risk of complications from COVID-19. However, data on the risk of allograft damage or death in kidney transplant recipients recovering from COVID-19 is limited. In addition, the first and second waves of the pandemic occurred at different times all over the world. In Turkey, the Health Minister confirmed the first case in March 2020; after that, the first wave occurred between March and August 2020; afterward, the second wave began in September 2020. This study aims to demonstrate the clinical presentations of kidney transplant recipients in the first two waves of the pandemic in Turkey and explore the impact of COVID-19 on clinical outcomes after the initial episode. Methods: Patients with COVID-19 from seven centers were included in this retrospective cohort study. Initially, four hundred and eighty-eight kidney transplant recipients diagnosed with COVID-19 between 1 March 2020 to 28 February 2021 were enrolled. The endpoints were the occurrence of all-cause mortality, acute kidney injury, cytokine storm, and acute respiratory distress syndrome. In addition, longer-term outcomes such as mortality, need for dialysis, and allograft function of the surviving patients was analyzed. Results: Four hundred seventy-five patients were followed up for a median of 132 days after COVID-19. Forty-seven patients (9.9%) died after a median length of hospitalization of 15 days. Although the mortality rate (10.1% vs. 9.8%) and intensive care unit admission (14.5% vs. 14.5%) were similar in the first two waves, hospitalization (68.8% vs. 29.7%; p < 0.001), acute kidney injury (44.2% vs. 31.8%; p = 0.009), acute respiratory distress syndrome (18.8% vs. 16%; p = 0.456), and cytokine storm rate (15.9% vs. 10.1%; p = 0.072) were higher in first wave compared to the second wave. These 47 patients died within the first month of COVID-19. Six (1.4%) of the surviving patients lost allografts during treatment. There was no difference in the median serum creatinine clearance of the surviving patients at baseline (52 mL/min [IQR, 47–66]), first- (56 mL/min [IQR, 51–68]), third- (51 mL/min [IQR,48–67]) and sixth-months (52 mL/min [IQR, 48–81]). Development of cytokine storm and posttransplant diabetes mellitus were independent predictors for mortality. Conclusions: Mortality remains a problem in COVID-19. All the deaths occur in the first month of COVID-19. Also, acute kidney injury is common in hospitalized patients, and some of the patients suffer from graft loss after the initial episode.
- 6 February 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (10) , 2117-2125
COVID-19 in chronic kidney disease: a retrospective, propensity score-matched cohort study
Background The prognostic factors for COVID-19 in patients with chronic kidney disease (CKD) are uncertain. We conducted a study to compare clinical and prognostic features between hospitalized COVID-19 patients with and without CKD. Methods Fifty-six patients with stage 3–5 CKD and propensity score-matched fifty-six patients without CKD were included in the study. Patients were followed-up at least fifteen days or until death after COVID-19 diagnosis. The endpoints were death from all causes, development of acute kidney injury (AKI) or cytokine release syndrome or respiratory failure, or admission to the intensive care unit (ICU). Results All patients were reviewed retrospectively over a median follow-up of 44 days (IQR, 36–52) after diagnosis of COVID-19. Patients with CKD had higher intensive care unit admission and mortality rates than the patients without CKD, but these results did not reach statistical significance (16 vs. 19; p = 0.54 and 11 vs. 16, p = 0.269, respectively). The frequency of AKI development was significantly higher in predialysis patients with CKD compared to the other group (8 vs. 5; p < 0.001), but there was no significant difference between the groups in terms of cytokine release syndrome (13 vs. 8; p = 0.226), follow-up in the ICU (19 vs. 16; p = 0.541), and respiratory failure (25 vs. 22, p = 0.566). Multivariate logistic regression analysis revealed that respiratory failure and AKI were independent risk factors for mortality. Conclusion The mortality rates of COVID-19 patients with CKD had higher than COVID-19 patients without CKD. Also, AKI and respiratory failure were independently related to mortality.
- 6 February 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (10) , 2117-2125
COVID-19 in chronic kidney disease: a retrospective, propensity score-matched cohort study
Background The prognostic factors for COVID-19 in patients with chronic kidney disease (CKD) are uncertain. We conducted a study to compare clinical and prognostic features between hospitalized COVID-19 patients with and without CKD. Methods Fifty-six patients with stage 3–5 CKD and propensity score-matched fifty-six patients without CKD were included in the study. Patients were followed-up at least fifteen days or until death after COVID-19 diagnosis. The endpoints were death from all causes, development of acute kidney injury (AKI) or cytokine release syndrome or respiratory failure, or admission to the intensive care unit (ICU). Results All patients were reviewed retrospectively over a median follow-up of 44 days (IQR, 36–52) after diagnosis of COVID-19. Patients with CKD had higher intensive care unit admission and mortality rates than the patients without CKD, but these results did not reach statistical significance (16 vs. 19; p = 0.54 and 11 vs. 16, p = 0.269, respectively). The frequency of AKI development was significantly higher in predialysis patients with CKD compared to the other group (8 vs. 5; p < 0.001), but there was no significant difference between the groups in terms of cytokine release syndrome (13 vs. 8; p = 0.226), follow-up in the ICU (19 vs. 16; p = 0.541), and respiratory failure (25 vs. 22, p = 0.566). Multivariate logistic regression analysis revealed that respiratory failure and AKI were independent risk factors for mortality. Conclusion The mortality rates of COVID-19 patients with CKD had higher than COVID-19 patients without CKD. Also, AKI and respiratory failure were independently related to mortality.
- 28 April 2018
- Published by Springer Nature in CEN Case Reports
- Vol. 7 (2) , 229-233
Extreme hypercalcemia in a kidney transplant recipient
Post-transplant hypercalcemia is a major problem in renal transplant recipients, which may negatively affect both graft and patient survival. In this paper, we present a 66-year-old male kidney transplant recipient, who was admitted to our clinic with symptoms of fever, nausea, vomiting and lethargy. Laboratory data showed good renal function; however, a serum calcium level of 22.1 mg/dL. The patient was treated by isotonic saline together with furosemide and methylprednisolone. Because of treatment resistance, subcutaneous calcitonin and ibandronate were added to the treatment protocol as well. Since all these medications were not effective, hemodialysis with low-calcium (1.25 mmol/L) dialysate was applied for three consecutive days, which resulted in normalization of serum calcium. Several investigations were carried out for diagnosing the underlying etiology. Positron-emission tomography (PET)/CT revealed a strong diffuse uptake of FDG in the bones and spleen. A bone marrow biopsy showed diffuse interstitial infiltration of CD20 + neoplastic B cells and, thus, post transplant lymphoproliferative disease (PTLD) was diagnosed. Tacrolimus was switched to everolimus, mycophenolate mofetil was stopped, while treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was initiated. Despite all therapeutic interventions, the patient died of septic shock in the intensive care unit on the 10th day of emergency service admission. Importance of hemodialysis as an emergent treatment modality in extreme hypercalcemia, and unfavorable course of PTLD were underlined.
- 28 April 2018
- Published by Springer Nature in CEN Case Reports
- Vol. 7 (2) , 229-233
Extreme hypercalcemia in a kidney transplant recipient
Post-transplant hypercalcemia is a major problem in renal transplant recipients, which may negatively affect both graft and patient survival. In this paper, we present a 66-year-old male kidney transplant recipient, who was admitted to our clinic with symptoms of fever, nausea, vomiting and lethargy. Laboratory data showed good renal function; however, a serum calcium level of 22.1 mg/dL. The patient was treated by isotonic saline together with furosemide and methylprednisolone. Because of treatment resistance, subcutaneous calcitonin and ibandronate were added to the treatment protocol as well. Since all these medications were not effective, hemodialysis with low-calcium (1.25 mmol/L) dialysate was applied for three consecutive days, which resulted in normalization of serum calcium. Several investigations were carried out for diagnosing the underlying etiology. Positron-emission tomography (PET)/CT revealed a strong diffuse uptake of FDG in the bones and spleen. A bone marrow biopsy showed diffuse interstitial infiltration of CD20 + neoplastic B cells and, thus, post transplant lymphoproliferative disease (PTLD) was diagnosed. Tacrolimus was switched to everolimus, mycophenolate mofetil was stopped, while treatment with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) was initiated. Despite all therapeutic interventions, the patient died of septic shock in the intensive care unit on the 10th day of emergency service admission. Importance of hemodialysis as an emergent treatment modality in extreme hypercalcemia, and unfavorable course of PTLD were underlined.
- Open Access
- 1 September 2017
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 80 (3) , 104-110
EFFECT OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE POLYMORPHISMS ON THE PLASMA CONCENTRATIONS OF MYCOPHENOLIC ACID IN TURKISH RENAL TRANSPLANT PATIENTS
Amaç: Mikofenolik asit ’ in (MPA) farmakokinetiğinde bireyler arasında farklılıklar vardır. MPA öncelikle uridin difosfat-glukuronosiltransferazlar (UGT) tarafından metabolize olur. UGT2B7, MPA glukuronidasyonu için önemli bir UGT ’ dir. Çalışmanın amacı, Türk böbrek nakilli hastalarda UGT2B7 His268Tyr (802C>T) polimorfizmlerinde MPA farmakokinetiğini incelemektir. Gereç ve Yöntem: Çalışmaya renal transplant yapılmış, 65 hasta dahil edildi. UGT2B7 His268Tyr (802C>T) genotiplemesi PCR-RFLP kullanılarak yapıldı. MPA konsantrasyonları Klonlanmış Enzim Donör Immunoassay (CEDIA) ile belirlendi. Tüm hastalar çalışma süresi boyunca akut rejeksiyon ve greft fonksiyonu açısından izlendi. Bulgular: Hastalar arasında UGT2B7 (802C>T) CC, CT ve TT genotip frekansları sırasıyla 24 (%36,9), 36 (%55,4) ve 5 (%7,7) idi. Üçüncü ve altıncı aylarda MPA düzeyleri UGT2B7 (802C>T) TT taşıyıcılarında CT ve CC taşıyanlara göre sırasıyla istatistiksel olarak anlamlı derecede yüksek bulundu (p=0,038, p=0,021). MPA ’ nın doz/kan konsantrasyonu oranı nakil sonrası altıncı ayda TT genotipi taşıyanlarda CC ve CT genotipi taşıyanlara göre daha yüksekti (p=0,042). TT genotipi taşıyan bireyler sırasıyla CC ve CT genotiplerine kıyasla üçüncü ve altıncı ayda düşük doz gereksinimleri göstermişlerdir (p=0,109, p=0,238). Ayrıca UGT2B7 (802C>T) polimorfizmi ile akut rejeksiyon arasında bir ilişki bulunmamıştır (p>0,05). Sonuç: Bizim sonuçlarımız, böbrek nakilli hastalarda UGT2B7 (802C>T) polimorfizmi ile MPA farmakokinetiği arasında bir korelasyon olduğunu göstermiştir. UGT2B7 polimorfizminin saptanması, en uygun MPA kan konsantrasyonları hedefi belirlenmesine yardımcı olabilir.
- 1 September 2017
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 80 (3) , 104-110
Open AccessEFFECT OF URIDINE DIPHOSPHATE-GLUCURONOSYLTRANSFERASE POLYMORPHISMS ON THE PLASMA CONCENTRATIONS OF MYCOPHENOLIC ACID IN TURKISH RENAL TRANSPLANT PATIENTS
Amaç: Mikofenolik asit ’ in (MPA) farmakokinetiğinde bireyler arasında farklılıklar vardır. MPA öncelikle uridin difosfat-glukuronosiltransferazlar (UGT) tarafından metabolize olur. UGT2B7, MPA glukuronidasyonu için önemli bir UGT ’ dir. Çalışmanın amacı, Türk böbrek nakilli hastalarda UGT2B7 His268Tyr (802C>T) polimorfizmlerinde MPA farmakokinetiğini incelemektir. Gereç ve Yöntem: Çalışmaya renal transplant yapılmış, 65 hasta dahil edildi. UGT2B7 His268Tyr (802C>T) genotiplemesi PCR-RFLP kullanılarak yapıldı. MPA konsantrasyonları Klonlanmış Enzim Donör Immunoassay (CEDIA) ile belirlendi. Tüm hastalar çalışma süresi boyunca akut rejeksiyon ve greft fonksiyonu açısından izlendi. Bulgular: Hastalar arasında UGT2B7 (802C>T) CC, CT ve TT genotip frekansları sırasıyla 24 (%36,9), 36 (%55,4) ve 5 (%7,7) idi. Üçüncü ve altıncı aylarda MPA düzeyleri UGT2B7 (802C>T) TT taşıyıcılarında CT ve CC taşıyanlara göre sırasıyla istatistiksel olarak anlamlı derecede yüksek bulundu (p=0,038, p=0,021). MPA ’ nın doz/kan konsantrasyonu oranı nakil sonrası altıncı ayda TT genotipi taşıyanlarda CC ve CT genotipi taşıyanlara göre daha yüksekti (p=0,042). TT genotipi taşıyan bireyler sırasıyla CC ve CT genotiplerine kıyasla üçüncü ve altıncı ayda düşük doz gereksinimleri göstermişlerdir (p=0,109, p=0,238). Ayrıca UGT2B7 (802C>T) polimorfizmi ile akut rejeksiyon arasında bir ilişki bulunmamıştır (p>0,05). Sonuç: Bizim sonuçlarımız, böbrek nakilli hastalarda UGT2B7 (802C>T) polimorfizmi ile MPA farmakokinetiği arasında bir korelasyon olduğunu göstermiştir. UGT2B7 polimorfizminin saptanması, en uygun MPA kan konsantrasyonları hedefi belirlenmesine yardımcı olabilir.
- 1 April 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (3) , 436-439
Prevalence of Human Herpesvirus-8 and BK Polyoma Virus Infections in End-stage Renal Disease and the Influence of Renal Transplantation
- 1 April 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (3) , 436-439
Prevalence of Human Herpesvirus-8 and BK Polyoma Virus Infections in End-stage Renal Disease and the Influence of Renal Transplantation